Fibrillar and oligomeric beta-amyloid as distinct local biomarkers for Alzheimer's disease.
Beta-amyloid is a key component of Alzheimer's disease (AD) pathology. Researchers in both academic and industry are actively pursuing the development of imaging tracers and techniques to noninvasively measure local levels of beta-amyloid in the Alzheimer's brain. This presentation summarizes recent data and discusses the opportunities and challenges of imaging plaques containing fibrillar beta-amyloid for the early diagnosis and therapeutic monitoring of amyloid targeted therapies. Further, the value and feasibility of measuring the recently described soluble oligomeric form of beta-amyloid as an alternative noninvasive biomarker is also discussed.
Montalto
Michael C
MC
Molecular Imaging and Diagnostics Advanced Technology Program, Biosciences, GE Global Research Center, Niskayuna, New York, USA. montalto@crd.ge.com
Farrar
Gill
G
Hehir
Cristina Tan
CT
D000544:Alzheimer Disease / Q000378:metabolism* / Q000473:pathology*; D016229:Amyloid beta-Peptides / Q000378:metabolism* / Q000648:ultrastructure*; D015415:Biomarkers; D001812:Blood-Brain Barrier / Q000502:physiology; D001921:Brain / Q000473:pathology; D001923:Brain Chemistry / Q000502:physiology; D006801:Humans; D058225:Plaque, Amyloid / Q000378:metabolism* / Q000473:pathology*
D016229:Amyloid beta-Peptides; D015415:Biomarkers